What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.

ABSTRACT: INTRODUCTION:Metformin is the recommended initial treatment in type 2 diabetes mellitus (T2DM), but when this does not give adequate glucose control the choice of which second-line drug to use is uncertain as none have been found to have a better overall glycaemic response. In this real-world study dipeptidyl peptidase 4 inhibitors (DPP4i), sulphonylureas (SU), thiazolidinediones (TZD) and sodium glucose co-transporter 2 inhibitors (SGLT2i) were compared for their effectiveness in lowering glycated haemoglobin (HbA1c) levels for a particular individual based on their clinical characteristics. METHODS:A retrospective analysis was undertaken of electronic health records of people with T2DM prescribed metformin alongside a DPP4i, SU, TZD or SGLT2i at second-line. Regression modelling was used

SUBMITTER: Strain WD 

PROVIDER: S-EPMC7261289 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature